Related Experiment Video
Updated: Jun 6, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Ethical considerations in CYP2D6 genotype testing for codeine-prescribed breastfeeding mothers
M Kurtz1, P Black Golde, N Berlinger
1Yale-New Haven Hospital, New Haven, Connecticut, USA.
Abstract:
In this issue, Madadi et al. report on interviews with codeine-prescribed breastfeeding mothers concerning preferences and attitudes toward receiving their CYP2D6 genotype and overall study findings. We address three sets of ethics questions raised by this article. Should genetic information be disclosed to research participants in genetic research? What should clinicians take into account when considering this genetic test in managing infant opioid toxicity risk? What conditions support or hinder the integration of genetic information into patient care?
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drug toxicity: Idiosyncratic Reactions
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase